Clinical trials: Alzheimer Dementia
Alzheimer's Disease
QTc Study of Rosi XR in Healthy Volunteers
This study is a randomised double blind, parallel group, and will evaluate the effects of repeat oral doses of RSG- XR for 21 days on the QTc interval compared to placebo in a population of healthy adult males and females.
- Trial name
- Rosi XR (NCT00884533)
- Testing
- Rosi XR, Moxifloxacin
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
This is a Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Multiple Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers and Subjects with MCI or…
- Trial name
- NCT06194552
- Testing
- NTRX-07
- Where
- 2 sites in United States, Hungary
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NeuroTherapia, Inc.
Alzheimer's Disease
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD.
- Trial name
- NCT00575055
- Testing
- Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
- Where
- 186 sites in United States
- Volunteers
- 1,121 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease, Mild Cognitive Impairment
Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease
This is a prospective cohort study for cognitively normal (young and old), mild cognitive impairment, and Alzheimer's disease people
- Trial name
- KBASE (NCT02137460)
- Where
- South Korea
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Alzheimer Disease
Effects of Heart Rate Oscillations During Meditation on Plasma Biomarkers of Alzheimer's Disease
In the current study, we will examine how two types of concentration meditation practices affect plasma biomarkers of Alzheimer's Disease (AD).
- Trial name
- NCT06210035
- Testing
- Belly-focus meditation, Belly-focus meditation with slow breathing
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer's Disease
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and…
- Trial name
- NCT01716897
- Testing
- E2609
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08161842) and how it is processed by the body. This is the first time PF-08161842 will be given to people.
- Trial name
- NCT07897708
- Testing
- PF-08161842
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Pfizer
Delirium, Cognitive Impairment
Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study
Cognitive skills are essential to live independently, manage finances, maintain employment, and function in society. Loss of these cognitive skills puts a tremendous burden on society as seen with dementias, Alzheimer's disease…
- Conditions
- Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma
- Trial name
- INSIGHT-ICU (NCT03098459)
- Testing
- Non-interventional observational prospective cohort study
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer's Disease, Mild Cognitive Impairment
FluoroAv45 Imaging Research-in Alzheimer's Disease
Rationale: improving the early detection of AD at prodromal pre-dementia stages has become a major matter of concern. There is now an important body of literature stating that early isolated cognitive deficits (Mild Cognitive…
- Trial name
- FAIR-AD (NCT01325259)
- Testing
- neuropsychologic assessment, [18F]AV-45 PET, 18-FDG PET
- Where
- 4 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Alzheimer Disease (AD), Alzheimer Dementia
Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
Preliminary clinical trial results indicate that Aβ-targeting monoclonal antibody drugs can delay disease progression more effectively.
- Conditions
- Alzheimer Disease (AD), Alzheimer Dementia, Mild Cognitive Impairment (MCI)
- Trial name
- NCT07152418
- Testing
- Lecanemab 10 mg/kg, Conventional anti-dementia treatment group
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Prodromal Alzheimer's Disease, Cerebral Vascular Disorder
Hyperbaric Oxygen Therapy for Prodromal Alzheimer´s Disease With Cerebrovascular Disease
Alzheimer´s disease is a devastating illness that effects the patients as well as their family members. Its prevalence increases exponentially and the burden on the healthcare system is enormous.
- Conditions
- Prodromal Alzheimer's Disease, Cerebral Vascular Disorder, Mild Cognitive Impairment, Vascular Cognitive Impairment
- Trial name
- NCT05349318
- Testing
- Hyperbaric oxygen therapy
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Assaf-Harofeh Medical Center
Agitation in Patients With Dementia of the Alzheimer's Type
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimer's type.
- Trial name
- NCT03393520
- Testing
- AVP-786
- Where
- 211 sites in United States, Australia and 9 more
- Volunteers
- 601 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Early Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype.
- Trial name
- APOLLOE4 (NCT04770220)
- Testing
- Experimental: ALZ-801
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Alzheon Inc.
Alzheimer's Disease, Dementia
Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease
There are few pharmacological treatments available for Alzheimer's disease, including drugs called cholinesterase inhibitors: donepezil, galantamine, and rivastigmine.
- Trial name
- NCT02035982
- Testing
- Cholinesterase Inhibitor
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Sunnybrook Health Sciences Centre
Dementia
Escitalopram for Agitation in Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
- Trial name
- S-CitAD (NCT03108846)
- Testing
- Escitalopram
- Where
- 29 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- JHSPH Center for Clinical Trials
Alzheimer Disease, Narrative
Evaluation of the Effectiveness of Narrative Nursing
To explore the effects of narrative nursing on mental state, life ability and emotion of patients with Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Narrative, Depression, Anxiety
- Trial name
- NCT06473220
- Testing
- Narrative nursing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanjing Medical University
Healthy
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo
The purpose of this study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JNJ-54861911 which is currently being developed for the treatment of Alzheimer's Disease.
- Trial name
- NCT01827982
- Testing
- JNJ-54861911 1mg, JNJ-54861911 3 mg, JNJ-54861911 9 mg
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
Purpose: The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography…
- Trial name
- AV151 (NCT00605046)
- Testing
- SPECT scan
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Primary Progressive Aphasia(PPA), Progressive Aphasia
Remotely-supervised Neuromodulation in PPA
The goal of this clinical trial is to learn whether home-based brain stimulation combined with virtual speech-language therapy can improve communication abilities in adults with logopenic variant primary progressive aphasia…
- Conditions
- Primary Progressive Aphasia(PPA), Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease, Logopenic Progressive Aphasia (LPA)
- Trial name
- NCT07260253
- Testing
- Lexical Retrieval Cascade Treatment, Remotely Supervised Transcranial Direct Current Stimulation- Active
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Maya Henry
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.